<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4892">
  <stage>Registered</stage>
  <submitdate>24/03/2015</submitdate>
  <approvaldate>24/03/2015</approvaldate>
  <nctid>NCT02401139</nctid>
  <trial_identification>
    <studytitle>Ketamine Trial for the Treatment of Depression</studytitle>
    <scientifictitle>Ketamine Therapy Among Patients With Treatment-resistant Depression: a Randomised, Double-blind, Placebo-controlled Trial: Pilot Phase</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>HREC 15009</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Unipolar Depression</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Ketamine
Treatment: drugs - Placebo

Active Comparator: Treatment arm - Ketamine

Placebo Comparator: Placebo arm - Placebo


Treatment: drugs: Ketamine


Treatment: drugs: Placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Montgomery Asberg Depression Rating Scale for Depression (MADRS)</outcome>
      <timepoint>4 weeks</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Individuals will be eligible for enrolment on the basis of:

          -  major depressive disorder for at least three months duration

          -  an inadequate response to at least 2 adequate antidepressants

          -  MADRS = 20

        Patients will be excluded on the basis of:

          -  History of psychosis

          -  History of bipolar disorder

          -  Any unstable medical or neurologic condition

          -  Any Axis I disorder other than MDD judged to be primary presenting problem

          -  Planned major changes to psychotropic medication

          -  Significant risk of suicide

          -  Planned or probable use of ECT

          -  Age under 16 years, or 16-17 years without parental consent

          -  Substance abuse or dependence in previous 6 months

          -  Any history of abuse of ketamine or phencyclidine

          -  Contraindication to the use of ketamine

          -  Planned use of ketamine

          -  Women of childbearing potential not taking reliable contraception

          -  Likely non-compliance with trial treatment

          -  Other condition judged by the treating clinician as likely to impact on the ability of
             the participant to complete the trial</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/09/2015</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Brain &amp; Mind Research Institute (BMRI), University of Sydney - Camperdown</hospital>
    <hospital>Black Dog Institute, University of New South Wales - Sydney</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2031 - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The University of New South Wales</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University of Sydney</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is a Randomized Controlled Trial, investigating the safety and efficacy of
      administration of ketamine as a potential treatment for depression.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02401139</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Colleen K Loo, MBBS, MD</name>
      <address>University of New South Wales</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Veronica Galvez Ortiz, MBBS, MD</name>
      <address />
      <phone>+61-2-93823720</phone>
      <fax />
      <email>v.galvezortiz@unsw.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>